Gland Pharma Latest Updates

Strong Q4 FY26 Financial Highlights Gland Pharma reported a massive surge in profitability for the fourth quarter ended March 31, 2026. Consolidated net profit (PAT) nearly doubled, jumping 96.6% year-on-year to ₹366.68 crore compared to ₹186.54 crore in Q4 FY25. Revenue from operations also expanded by 22.3% to reach ₹1,742.80 crore, driven by robust volume growth in its complex injectables portfolio. Annual Financial Performance For the full financial year 2025-26, the company's consolidated total income registered a 15.7% year-on-year increase, coming in at ₹6,746.98 crore against ₹5,830.11 crore in FY25. Full-year net profit tracked a sharp upward trajectory, surging 47.1% year-on-year to ₹1,027.32 crore compared to the ₹698.53 crore reported in the prior fiscal year. Significant Margin Expansion The pharmaceutical manufacturer recorded a substantial improvement in its operating leverage. Consolidated EBITDA for the quarter rose 48% year-on-year to ₹513 crore, with EBITDA margins expanding to 29.4% from 24.4% in the year-ago period. This operational improvement was heavily supported by a highly profitable core base business, which maintained an adjusted EBITDA margin of 38%. CDMO Business Emerges as Growth Engine The Contract Development and Manufacturing Organisation (CDMO) segment served as the primary catalyst behind the company's strong Q4 performance. The high-margin CDMO segment registered a significant 65% year-on-year revenue growth, contributing roughly 25% of the total consolidated revenue for the quarter as global pharmaceutical players continue to diversify their outsourced supply chains.